Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Assets (2020 - 2026)

Rani Therapeutics Holdings' Assets history spans 7 years, with the latest figure at $51.9 million for Q1 2026.

  • On a quarterly basis, Assets rose 115.04% to $51.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $51.9 million, a 115.04% increase, with the full-year FY2025 number at $58.6 million, up 60.02% from a year prior.
  • Assets came in at $51.9 million for Q1 2026, down from $58.6 million in the prior quarter.
  • The five-year high for Assets was $115.3 million in Q1 2022, with the low at $10.1 million in Q3 2025.
  • Historically, Assets has averaged $63.7 million across 5 years, with a median of $57.9 million in 2023.
  • Biggest five-year swings in Assets: plummeted 76.71% in 2025 and later soared 115.04% in 2026.
  • Year by year, Assets stood at $108.0 million in 2022, then tumbled by 46.39% to $57.9 million in 2023, then plummeted by 36.75% to $36.6 million in 2024, then soared by 60.02% to $58.6 million in 2025, then fell by 11.5% to $51.9 million in 2026.
  • Business Quant data shows Assets for RANI at $51.9 million in Q1 2026, $58.6 million in Q4 2025, and $10.1 million in Q3 2025.